Pamela S. Runyon

Pamela S. Runyon serves as a Contracting Officer responsible for managing the acquisition of in-vitro diagnostic substances and related laboratory testing technologies. In this role, she ensures compliance with federal procurement regulations while facilitating timely and effective contract awards that support critical public health and medical research initiatives. Her portfolio centers on complex, high-precision biological assays and reagents used in clinical diagnostics, requiring deep technical understanding of laboratory instrumentation, regulatory standards, and supply chain integrity for sensitive medical products. Runyon cultivates strategic relationships with a diverse base of manufacturers and suppliers specializing in diagnostic reagents, assay kits, and certified reference materials. While no single contractor dominates her portfolio, she consistently engages with firms possessing validated Good Manufacturing Practices (GMP) certifications and FDA-regulated production capabilities. Her contracting approach emphasizes performance-based outcomes, rigorous technical evaluation, and contract administration aligned with Federal Acquisition Regulation (FAR) Part 12 commercial item procedures. She maintains a strong preference for non-set-aside acquisitions, with 100% of her awards issued under full and open competition. This reflects a deliberate focus on accessing the broadest possible pool of qualified manufacturers with the technical capacity to meet stringent quality and regulatory requirements for diagnostic substances. Her approach prioritizes technical merit and compliance over socioeconomic set-asides, ensuring mission-critical supplies are procured with maximum efficiency and reliability. Her primary procurement focus is NAICS 325413—In-Vitro Diagnostic Substance Manufacturing—where she specializes in the acquisition of proprietary reagents, monoclonal antibodies, nucleic acid amplification kits, and standardized control materials. Her domain expertise spans molecular diagnostics, immunoassay technologies, and laboratory-developed test (LDT) support systems, making her a key contact for vendors engaged in the development and commercialization of clinical diagnostic products.